These observations are in line with some more recent findings from the same group: in IBD patients switched to a second-line anti-TNF therapy due to immunogenicity, the addition of an immunomodulator seems to prevent ADA formation and to be associated with lower rates of clinical failure [117]. The gene discussed is TNF; the disease is inflammatory bowel disease.